Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates

A single injection of ML29 reassortant vaccine for Lassa fever induces low, transient viremia, and low or moderate levels of ML29 replication in tissues of common marmosets depending on the dose of the vaccination. The vaccination elicits specific immune responses and completely protects marmosets a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Vaccine Jg. 26; H. 41; S. 5246 - 5254
Hauptverfasser: Lukashevich, Igor S., Carrion, Ricardo, Salvato, Maria S., Mansfield, Keith, Brasky, Kathleen, Zapata, Juan, Cairo, Cristiana, Goicochea, Marco, Hoosien, Gia E., Ticer, Anysha, Bryant, Joseph, Davis, Harry, Hammamieh, Rasha, Mayda, Maria, Jett, Marti, Patterson, Jean
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Oxford Elsevier Ltd 26.09.2008
Elsevier
Elsevier Limited
Schlagworte:
Allergy and Immunology
Animals
Applied microbiology
Arenaviruses
Biological and medical sciences
Biomedical research
Callithrix
Callithrix - immunology
CD3 Complex - immunology
Chlorocebus aethiops
Enzymes
Female
Fundamental and applied biological sciences. Psychology
Gene Expression Regulation - immunology
Genomes
Histology
Human viral diseases
Humans
Immunity, Cellular - immunology
Immunogenicity
Infectious diseases
Kinases
Lassa fever
Lassa Fever - immunology
Lassa Fever - pathology
Lassa Fever - prevention & control
Lassa fever and arenovirus diseases
Lassa virus - genetics
Lassa virus - immunology
Lassa virus - isolation & purification
Leukocytes, Mononuclear - immunology
Lipopolysaccharide Receptors - immunology
Male
Medical sciences
Microbiology
Monkeys & apes
Protection
Proteins
Reassortant Viruses - genetics
Reassortant Viruses - immunology
RNA polymerase
Safety
Studies
Survival Analysis
T-Lymphocytes - immunology
Tropical viral diseases
Vaccine
Vaccines
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Vero Cells
Viral diseases
Viremia - immunology
Viruses
Nigeria
Guinea
Sierra Leone
Lassa fever
Vaccine
Arenaviruses
Protection
Hemorrhagic fever
Genetic reassortment
Monkey
Infection
Vertebrata
Mammalia
Immunogenicity
Efficiency
Viral disease
Arbovirus disease
Primates
ISSN:0264-410X, 1873-2518
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:A single injection of ML29 reassortant vaccine for Lassa fever induces low, transient viremia, and low or moderate levels of ML29 replication in tissues of common marmosets depending on the dose of the vaccination. The vaccination elicits specific immune responses and completely protects marmosets against fatal disease by induction of sterilizing cell-mediated immunity. DNA array analysis of human peripheral blood mononuclear cells from healthy donors exposed to ML29 revealed that gene expression patterns in ML29-exposed PBMC and control, media-exposed PBMC, clustered together confirming safety profile of the ML29 in non-human primates. The ML29 reassortant is a promising vaccine candidate for Lassa fever.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
M.S.S. and J.P. contributed equally to this paper.
Corresponding author. Tel.: +1 410 706 1366; fax: +1 410 706 5198. E-mail address: ilukashevich@ihv.umaryland.edu (I.S. Lukashevich).
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2008.07.057